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Background: The progress in computer-aided drug design (CADD) approaches over the past decades accelerated
the early-stage pharmaceutical research. Many powerful standalone tools for CADD have been developed in
academia. As programs are developed by various research groups, a consistent user-friendly online graphical
working environment, combining computational techniques such as pharmacophore mapping, similarity calculation,
scoring, and target identification is needed.
Results: We presented a versatile, user-friendly, and efficient online tool for computer-aided drug design based on
pharmacophore and 3D molecular similarity searching. The web interface enables binding sites detection, virtual
screening hits identification, and drug targets prediction in an interactive manner through a seamless interface to
all adapted packages (e.g., Cavity, PocketV.2, PharmMapper, SHAFTS). Several commercially available compound
databases for hit identification and a well-annotated pharmacophore database for drug targets prediction were
integrated in iDrug as well. The web interface provides tools for real-time molecular building/editing, converting,
displaying, and analyzing. All the customized configurations of the functional modules can be accessed through
featured session files provided, which can be saved to the local disk and uploaded to resume or update the history work.
Conclusions: iDrug is easy to use, and provides a novel, fast and reliable tool for conducting drug design experiments. By
using iDrug, various molecular design processing tasks can be submitted and visualized simply in one browser without
installing locally any standalone modeling softwares. iDrug is accessible free of charge at http://lilab.ecust.edu.cn/idrug.
Keywords: Online drug design platform, Cavity detection, Pharmacophore search, 3D similarity calculation, Target
predictionBackground
Computer-aided drug design (CADD) is a widely used
term that represents computational tools and sources for
the storage, management, analysis and modeling of
compounds [1]. Benefiting from the dramatic increase
of biomacromolecular and small molecular information,
CADD techniques are used at various stages of a
drug-discovery project, from target identification and
validation to lead discovery and optimization, even
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unless otherwise stated.A huge body of CADD software has been developed
over the years in many different research groups [3-11].
However, most molecular design packages, with single
client interface and powerful algorithms, may require
separate license keys to be purchased individually. In
addition, due to the complexity and diversity of molecular
design procedures, sometimes even trained computational
chemists can not perfectly excel in what they are computing
[12]. In parallel, the open source and easily accessible
software, which provides a great opportunity to perform
research in CADD, has often encountered two main
problems when being used by medicinal chemists
[13]. First, in many instances the authors of CADD
software pay more attention to scientific details rather
than the usability of software, thus making it rarely
associated with the graphical user interface and difficult to
use for non-expert experimentalists. Second, individuall Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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produces a specific output format, making users incapable
of combining different programs.
The striking growth of web technologies provides an
alternative strategy to offer the possibility of accessing and
running computational chemistry tools directly on the web
with a simplified user interface. The major advantages of
these web-based solutions are that users can submit models
and data to the online servers without regularly download-
ing and updating the data collections and tools to their local
disks. An increasing number of web applications for per-
forming molecular modeling and processing are also avail-
able for end users [14-17]. However, these tools are always
not able to integrate various molecular design programs
and enormous data collections to meet the systematic oper-
ations of users to achieve the best results [18]. Besides, even
if some initiatives combining different computational pro-
grams exists, e.g. for e-LEA3D [19], Sanjeevini [20], only
focused on structure-based drug design such as molecular
docking and de novo drug design which rely on the know-
ledge of the given structure of the target macromolecule.
Here, we developed an online interactive platform,
termed iDrug, to break expensive commercial suites and
command line barrier and introduce a user-friendly web
environment to conduct 3D molecular similarity calculation
and to construct pharmacophore models for virtual
screening. The user may select the molecular processing
engine used by iDrug and setup and initiate jobs. Currently
the system allows access to derive pharmacophore models
directly from the given receptor regardless of a molecular
3D structure in the corresponding binding pose conform-
ation provided as the reference (Cavity [8] and PocketV2
[21]); generate novel molecules for the given site using
pharmacophore mapping approach; predict targets of a
chemical of interest such as drugs, lead compounds and
natural products (PharmMapper [22]); and rank candidates
based on similarity-based database searching (SHAFTS
[7,23,24]). Different modules described above (Table 1) haveTable 1 List of computational techniques supported by
iDrug
Name Method Refs Free foracademia
Cavtiy
Detect and score potential binding











SHAFTS 3D similarity calculation [7,23] Yes
Cyndi Molecular conformation generation [38,39] Yes
Pybel
Python wrapper for the OpenBabel
cheminformatics toolkit
[25,26] Yesbeen incorporated, which work in a pipeline as depicted in
the architecture (Figure 1). It also features a session based
working bench to save, resume, and reuse the jobs
and configurations customized by users, which can be
accessed and updated through the interface easily. As
iDrug addresses common problems associated with
either biomacromolecule or small molecule, it is expected
to help both experts and non-specialists to achieve the
automated molecular design of daily research demands, as
well as being a routine adjunct to experimental studies.
Methods
Implementation and interface
The iDrug system was developed using Java on Apache
Tomcat Server. The platform back-end was developed in
Python programming language, with MySQL as the
database system, while the front-end is implemented with
JSP using JavaScript and AJAX technologies utilizing
the jQuery library. The open-source Java viewer Jmol
(http://www.jmol.org/) is used for 3D display and manipu-
lation of molecular structures. Pybel [25,26], a Python
wrapper of the OpenBabel toolkit, was used in backend for
molecular file parsing and converting.
The user interface of iDrug is shown in Figure 2. Users
can normally start a session by clicking the ‘Load’ button.
As iDrug provides pharmacophore- and similarity-based
tasks, the corresponding uploading dialog is grouped into
two modes: ‘pharmacophore work mode’ and ‘similarity
work mode’. After a successful submission, a unique Job ID
is assigned and used to access the computational results.
Result files associated with the completed jobs are stored at
the server for 3 months, which can be downloaded
for offline analysis within this period of time.
Chemical and drug target database
iDrug currently integrates the publicly accessible NCI
database [27] and the commercially available and biological
relevant compounds from ZINC [28], comprising over 3
million compounds with multiple 3D conformers pre-
generated to facilitate both pharmacophore and 3D simi-
larity based virtual screening. An in-house pharmacophore
database called PharmTargetDB [22] containing over 7,000
pharmacophore models derived from complex crystal
structures with corresponding protein target annotations is
incorporated in iDrug as well. The target protein annota-
tions including name, function, and involved indication/
disease were referred from DrugBank [29], BindingDB
[30], PDBBind [31], and PDTD [32] databases. The key
information for each database was summarized in Table 2.
Cavity detection and structure-based pharmacophore
modeling
Identification of protein cavities is of fundamental
importance for structure-based pharmacophore derivation.
Figure 1 Workflow of iDrug automating pharmacophore modeling using Cavity and Pocket v.2, screening with PharmMapper and
SHAFTS, and searching conformers using Cyndi. Common modules in iDrug platform are framed in black.
Figure 2 The iDrug interface. The task management is in the upper left and provides easy access to the full set of the history work. The Jmol-based
molecular viewer is in the middle and displays the query molecule and results structure. The query editor is shown in the bottom and supports the
interactive modification of the parameters based on the properties of the computational software. The results browser is on the right and displays the
complete results along with the available details. In this figure, potential targets of tamoxifen obtained from iDrug are shown as well as the target
pharmacophore model. On mouse over, a preview of the annotation information is displayed in a pop-up window, as shown for 2GPU in this example.
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Table 2 Data source of iDrug
Type Database Number of entities
Compounds
ZINC Lead-like 3,027,615
NCI Open Database 246,483
Targets PharmTargetDB 7,302
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on the surface of a given protein structure, and rank them
according to the corresponding druggability scores on
the basis of geometric shape, hydrogen bonding, and
hydrophobic effects. By comparison of the success
rate for the first-ranked prediction tested on the
PDBBind dataset, Cavity outperformed four popularly
used binding sites detection approaches (LIGSITEcsc,
Q-sitefinder, SURFNET, and PASS), indicating its accurate
prediction of relatively small binding sites on the surface
of a protein [8,33]. Li et al. customized LigBuilder 2.0
to generate and fit the shape of the Cyclophilin A
(CypA) binding site and finally obtained two highly
potent inhibitors with nanomolar inhibitory potencies
(2.59 nM and 1.52 nM) [34]. A receptor-based pharmaco-
phore modeling program Pocket v.2 was used to extract
pharmacophore features within cavities [21]. In this
approach, hotspot analysis and grid-based scoring were
used to identify essential pharmacophore features. As
suggested by case study results, Pocket v.2 can yield
consistent pharmacophore models for proteins with minor
conformational changes upon binding of different ligands,
indicating the robustness of the approach. Lai et al.
proposed a novel strategy that combined receptor-based
common pharmacophores with molecular docking. Three
compounds were identified through this strategy to inhibit
LTA4H-h and hnps-PLA2 simultaneously [35].
Normally, iDrug requires a protein 3D structure or
a known PDB accession code as input to derive
pharmacophore models. All binding sites along with
the extracted pharmacophore features will be displayed
and ranked by the druggability scores. A small molecular
3D structure in the corresponding binding poses
conformation can also be uploaded as the reference to
specify the position of the binding site and generate the
pharmacophore features representing the corresponding
interaction mode. It takes averagely 1–3 minutes for
binding sites detection, and the potential binding sites
can be interactively viewed and downloaded in PDB
files for off-line analysis, which includes the binding pocket
surface, the residues around the site, and key features of
the pharmacophore model derived from the site.
Pharmacophore mapping and virtual screening
For pharmacophore-based screening, iDrug employs a
pharmacophore mapping method called PharmMapperbased on feature triplet hashing and searching algorithm
[22]. Liu et al. discovered two potent IGF-1R kinase
inhibitors via hierarchical strategy based virtual screening
(pharmacophore screening and docking), which efficiently
reduced the number of “nonhits” passed to docking stage
and consequently reduced the computational cost [36].
The query pharmacophore model can be derived from
the potential binding sites detected previously or user
customized ones. iDrug allows interactive editing of
the features of the pharmacophore query like feature
type, positions, and size of the tolerance spheres.
Pharmacophore searching is performed against the
available or user uploaded databases. The hit compounds
are compiled into the table with the corresponding
original weblinks whereas applicable, and ranked by the fit
values with the query. The superimposed mode of the
molecules onto the pharmacophore query along with the
corresponding binding site can be interactively visualized
in Jmol applet.
Target identification
iDrug uses the reverse pharmacophore mapping procedure
to predict potential drug targets. Qian et al. discovered a
novel series of acenaphtho[1,2-b]pyrrole derivatives as
potent FGFR1 inhibitors by using this in silico targets
screening approach [37]. The results were subsequently
validated by enzyme-linked immunosorbent assay. The
platform takes a single drug-like molecule or natural
product chemical structure as an input and automatically
perceives all chemotype features of the query molecule.
Users are allowed to modify the perceived pharmacophore
model and search the pharmacophore target database with
it. The results can also be filtered in terms of both the
number of returned results and the properties of the algo-
rithm. Since the geometric matching alignment and scoring
method uses rigid conformations, multiple conformers of
each query molecule must be generated. In-house program
Cyndi [38,39], which uses a multi-objective evolution
algorithm method for conformer searching, was chosen by
default to generate multiple conformation. Additionally, the
minimum number of each pharmacophore feature type and
a fit score cutoff can be specified to discard those target
pharmacophore models, of which the corresponding values
are less than the threshold. On average, the total time
consumed by the complete screening and scoring protocol
ranges from 1-2 h depending on the flexibility of the input
molecule and filter parameters assigned by the user.
Upon completion of the computations, the results of
the hit target pharmacophore models are demonstrated
in the form of a ranked list. Each row contains the
protein ID, which is a hyperlink points to the PDB
website [40], the target name, the fit values between the
small molecule and the pharmacophores, and a unique
orientation of a conformation of the query along with
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the Jmol applet. Detailed annotations of the hit targets
are presented in a pop-up window when the cursor
moves over the corresponding PDB codes. Alternatively,
a downloadable zip file containing the aligned pose
with the corresponding pharmacophore model and the
complete targets information in CSV format is accessible
for each returned match.Figure 3 Pharmacophore depiction as used in this study on top
of PDB entry: 1AQ1 (note that 1AQ1 with its cocrystallized
ligand is used as a reference).Similarity search
For the implementation of ligand-based searching, iDrug
adopts an efficient 3D similarity calculation method
SHAFTS, which is designed to integrate the strength
of pharmacophore matching and volumetric overlay
approaches [7]. Hits are determined by a hybrid similarity
score cut-off and alignment poses of compounds will be
generated by enumerating all potential pharmacophore
feature triplets matches. Liu et al. discovered sixteen
compounds with IC50 < 20 μM, three of which showed
low micromolar inhibitory activities against p90 riboso-
mal S6 protein kinase 2 (RSK2) and exhibited selectivity
across a panel of related kinases using SHAFTS [23]. By
adopting the same strategy, Xu et al. reported a novel
pteridin-7(8H)-one epidermal growth factor receptor
(EGFR) inhibitor scaffold with potent and selective in-
hibitory activity against both wild-type and T790M/
L858R mutant EGFRs. The most remarkable agent
showed highly inhibitory activity against the growth of
gefitinib-resistant H1975 cells, making it a potential
lead for further development of EGFR kinase-related an-
ticancer drugs [41]. The results suggests that SHAFTS
is an efficient and powerful tool in scaffold hopping and
hit identification endeavors. Moreover, Shen et al.
used the evodiamine derivative as a probe to search
MDL/Symyx Drug Data Report (MDDR) [42] with
ChemMapper. The fourth ranked protein, topoisomer-
ase II (Top2), was a well-known antitumor target. Re-
laxation assay proved that the analogs of the natural
product are potent inhibitor against Top2, with stron-
ger activity than the well-known Top2α inhibitor eto-
poside [43].
A chemical structure (sketched online or uploaded in
multiple chemical structure file formats) is accepted as
the query to perform similarity searching. It takes hours
to days per search depending on the complexity of the
query molecule and the size of the library.
The outputs are generated as a list of compounds
sorted by similarity scores to the query and can be
downloaded in a mol2 file. The superimposed pose of
each hit with the query can be visualized interactively in
Jmol applet along with the molecular surface represen-
tation and perceived pharmacophore features by
SHAFTS.Results and discussion
Benchmarking study
To demonstrate potential applications of iDrug platform,
we performed pharmacophore-based virtual screening
libraries with the MUV data sets [44], molecular 3D
similarity-based virtual screening with the enhanced
Directory of Useful Decoys (DUD-E) [45] data sets, and
reversed pharmacophore mapping-based drug target
identification with the pharmacophore target database.
Receiver Operator Characteristic (ROC) curves, Area
Under the ROC Curves (AUC), and enrichment factors
(EF) were calculated after ranking compounds from the
MUV and DUD-E data sets. EF after x% of the library
screened were calculated according to the following
formula (Hitssampled = number of hits found at x% of the
database screened, Nsampled = number of compounds
screened of x% of the database, Ntotal = the number of
compounds in the entire database, Hitstotal = the number






Case 1: pharmacophore-based virtual screening
CDK2 (Cyclin-dependent kinase 2) is a protein kinase
whose pharmacophore features, depicting ligands that
target against the ATP binding site, are well described in
the literature [46]. We used iDrug to create pharmacophore
queries from the crystal structures of CDK2 (PDB:1AQ1).
The pharmacophore queries occupied by the bioactive
conformation of the ligand, which contain one H-bond
Table 3 AUC value and EF values at 0.5, 1, 2 and 5% for
CDK2 inhibitor pharmacophore-based virtual screening
AUC EF
0.63
0.5% 1.0% 2.0% 5.0%
2.5 1.3 2.5 2
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features, were selected as the hypotheses (Figure 3).
We create the compound sets using the virtual screening
dataset of CDK2 comprising 80 active compounds and
15000 decoy compounds [47]. The search of 249,242
conformers of 15080 compounds takes almost 20 minutes.
Without any prescreening, iDrug matches 50 out of 80
actives and 5641 out of 15000 decoys resulting in an
enrichment factor of 1.7. The AUC value is 0.63, indicating
that the overall enrichment is only slightly better than that
expected from a random selection (Table 3). This is an
important observation suggesting that though not so
effective in actives enrichment with single pharmacophore
model, iDrug enables fast prefiltering for large com-
pound collections before applying more accurate and
computationally expensive algorithms.
Case 2: target prediction
Tamoxifen, which is used as an adjuvant therapy in
the treatment of breast cancer, has been proved as a
multiple target drug. So far, tamoxifen and its active
metabolite, 4OH-tamoxifen, are known to interact with 16
targets. We have chosen to investigate 4OH-tamoxifen as
a test case for validation (the typical run takes less than an
hour). The 11 known targets of 4OH-tamoxifen retrieved
by iDrug are shown in Table 4. Other targets, includ-
ing microsomal antiestrogen binding site (AEBS) [48],Table 4 Retrieval of 11 targets of 4OH-Tamoxifen by
iDrug




Estrogen receptor-γ [52] 5.736 1VJB 0.01
Estradiol 17β-hydroxysteroid
dehydrogenase 1
[53] 4.111 1I5R 0.26
Dihydrofolate reductase [54] 3.777 1DG7 0.45
Glutathione S-transferase A1 [55] 3.655 1GSF 0.73
Prostaglandin G/H synthase 2 [56] 3.411 1PXX 1.36
Liver carboxylesterase 1 [57] 3.344 1YA4 1.59
Protein kinase C theta type [58] 3.171 1XJD 2.18
Calmodulin [59] 2.974 1XA5 3.63
Collagenase 3 [60] 2.945 3I7I 4.57
Alcohol dehydrogenase E chain [60] 2.881 1MGO 7.37
3-alpha-(or20-beta)-hydroxysteroid
dehydrogenase
[61] 2.835 1HDC 9.87cholesterol acyl transferase (ACAT) [48], cholesterol
epoxide hydrolase [49], hedgehog signaling [50], immuno-
globulin [51], are missed due to the limited coverage of
the pharmacophore database. In spite of this, the reverse
pharmacophore mapping approach, therefore, enables
11 of 16 experimentally confirmed tamoxifen targets
to be retrieved within 10% of the ranked database,
which is promising and reliable for a retrospective
target identification case.
Case 3: molecular 3D similarity-based screening
The crystal ligand structure of epidermal growth factor
receptor (EGFR, PDB:2RGP) was searched via iDrug.
The screening library was created using the DUD-E data
sets including 542 active compounds and 35,050
decoy compounds for a baseline enrichment of 1.5%. A
multiconformer library was generated using Cyndi with the
default settings (up to 200 conformers per a compound),
resulting in a library of 2,735,015 conformations.
The search of EGFR query in iDrug takes 12–14 hours.
The performance of iDrug with respect to compound
library enrichment, i.e., the fraction of true positives
versus the fraction of false positives, was visualized in
ROC. The corresponding AUC and enrichment values at
0.5, 1.0, 2.0, and 5.0% are calculated and reported, which
can be found in Table 5. The AUC value is 0.87 and the
EF value at the 0.5% level is 56.9, indicating highly
significant enrichment with respect to random ones.
Experimental
Compound data sets
Datasets from four different public sources were used. A
set of over 3 million compounds extracted from ZINC
[28] and NCI [27] were used for both pharmacophore
and 3D similarity based virtual screening. Cyndi [38]
was used to generate a maximum of 50 low-energy
conformations for each compound. The MUV data sets
are based on bioactivity data. MUV consists of 17
targets, each with 30 actives and 15000 decopys [44]. In
this study we reproduced the evaluation of Sanders et al
[47] and derived pharmacophore queries from the crystal
structure of CDK2 (PDB:1AQ1). The DUD-E was origin-
ally designed for benchmarking of docking methods [45].
A subset was later extracted for the use in 3D similarity-
based virutal screening experiments. The DUD-E contains
102 targets with 22886 clustered ligands drawn from
ChEMBL, each with 50 property-matched decoys drawnTable 5 AUC value and EF values at 0.5, 1, 2 and 5% for
EGFR inhibitor similarity virtual screening
AUC EF
0.87
0.5% 1.0% 2.0% 5.0%
56.9 42.9 28.5 13.6
Wang et al. Journal of Cheminformatics 2014, 6:28 Page 7 of 8
http://www.jcheminf.com/content/6/1/28from ZINC. In this study EGFR with 542 actives were used.
Besides, for the user uploaded target compounds, multi
conformations (at most 100) would be generated online
with Cyndi prior to virtual screening if the ‘Generate
Conformers’ is toggled on.
Target pharmacophore databases
The target protein structures co-complexed with small
molecules were selected from DrugBank, BindingDB,
PDBBind, and PDTD databases. All the small ligands
with molecular weight lower than 100, such as solvents,
buffers and metal cations, and all the cofactors with
molecular weight over 600, such as CoAs, polypeptides
and nucleic acids were regarded. For the proteins existing
as homopolymers, only one monomer was reserved
for analysis. For the proteins determined by NMR
with multiple structure models, only the first model
was selected for pharmacophore generation. LigandScout
[9] was used in the process of pharmacophore model
derivation. As a result, a database with 7302 pharmacophore
models were generated and stored in iDrug. This database
has been used in our previous publications [22].
Conclusions
We presented iDrug, a versatile web server for both
pharmacophore- and similarity-based virtual screening and
target identification to facilitate computational drug
discovery. The interface is easy-to-use and can be accessed
by user customized sessions to free them from installing
standalone softwares. iDrug provides ready-to-access com-
pounds and pharmacophore target databases for virtual
screening and target identification. Various applica-
tions like binding site identification, structure-based
pharmacophore derivation, conformational sampling,
pharmacophore searching, and 3D similarity calculation are
integrated as individual modules. It enables interactive
editing and refinement of pharmacophore hypothesis as
well as flexible customization of the parameters. The
featured job management system ensures the user privacy
and project tracking through a session-based mechanism.
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